ABSTRACT. Children with glycogen storage disease G-CSF, granulocyte colony-stimulating factor (GSD) type 1 b are susceptible to recurrent bacterial infec-GM-CSF, granulocyte-macrophage colony-stimulating tions and have chronic neutropenia accompanied by phagfactor ocytic cell dysfunction including decreased superoxide anrh, recombinant human ion (02-) generation, calcium (Ca2+) mobilization, and ANC, absolute neutrophil count chemotactic activity. Granulocyte colony-stimulating factor PMA, phorbol myristate acetate (G-CSF), a cytokine that corrects neutropenia in other Ca2+, calcium diseases, in vitro enhances f-Met-Leu-Phe-triggered neutrophil 0 2 -generation. Short-term pretreatment (15 min) of CSD l b neutrophils with G-CSF increased the rate of 02-production (p < 0.01); however, this rate was still significantly below the rate of 02-production in control
In both GSD type la and lb, hepatic defects prevent the neutrophils. Recombinant human E C S F (5 rglkgld) was conversion of glucose-6-phosphate to glucose, resulting in hyadministered s.c. to a GSD l b patient. Before treatment, poglycemia during fasting (1-5). In GSD la, the hepatic enzyme absolute neutrophil counts were c 500/mm3. Two d after glucose-6-phosphatase is defective, whereas in GSD lb the glu-G-CSF administration, the absolute neutrophil counts in-cose-6-phosphate translocase is affected. The clinical features of creased to 1333 and remained in the normal range during GSD 1 b are similar to those of GSD la, with the exception that a 12-mo follow-up period. In vivo, G-CSF therapy in-GSD 1 b patients are often neutropenic and are prone to recurrent creased f-Met-Leu-Phe-stimulated 0 2 -production to 52% infections, whereas GSD la patients are not (6-1 1). The recurof control after 1 mo, and by mo 4,02-production reached rent bacterial infections most commonly involve the skin, pericontrol levels. Our previous studies (J Clin Invest 56:196-rectal area, lungs, ears or urinary tract. Organisms that are most 202, 1990 ) demonstrated that decreased 02-production in frequently isolated include Staphylococcus aureus, group A neutrophils was associated with impaired Ca2+ mobiliza-Streptococcus, Streptococcus pneumoniae, and Escherichia coli tion. In vivo administration of G-CSF increased f-Met- (12) . Such infections usually respond poorly to treatment, and Leu-Phe-triggered Ca2+ mobilization by neutrophils to many patients require repeated, prolonged hospitalizations for 43% of control by mo 1 of G-CSF therapy and to 93% of i.v. antibiotics. control by mo 4, thus paralleling the improvements in 0 2 - Critical to host defense against infections are circulating phaggeneration. In contrast, G-CSF therapy had no effect on ocytic cells, namely neutrophils and monocytes. In addition to a the defective neutrophil chemotaxis. In summary, G-CSF diminished number of circulating neutrophils, there is evidence therapy produced a rapid increase in circulating neutrophils of functional defects including depressed respiratory burst activand a gradual correction of 02-production. Long-term ity and chemotaxis in phagocytic cells from GSD lb patients exposure to G-CSF may be required for correction of both that limit their ability to destroy invading microorganisms (8, neutropenia and 0 2 -production in GSD 1 b patients. (Pe-1 3-17). In previous studies, we have demonstrated decreased diatr Res 35: 84-90, 1994) 02-production associated with blunted Ca2+ mobilization in phagocytic cells from GSD 1 b patients (18, 19) . However, the Abbreviations specific phagocytic cell defect has yet to be identified. GSD, glycogen storage disease
With the discovery and cloning of growth factors such as G-et al. (31) . Mononuclear cells, separated from whole blood by Ficoll-Hypaque centrifugation, were suspended in Dulbecco's modified Eagle medium. The cell suspension was plated onto gelatin-coated tissue culture flasks and incubated at 37' C for 45 min in 5% CO2. Nonadherent cells were removed by washing the flasks several times. Adherent monocytes were then detached by incubation with 5 mM EDTA in Dulbecco's modified Eagle medium with 10% FCS. These cell populations were 92-96% monocytes, based on latex ingestion and nonspecific esterase staining. Fura-2 fluorescence spectroscopy. Cytosolic free Ca2+ concentrations were determined in fura-2 loaded neutrophils according to the method of Korchak et a/. (32) . Cells were incubated in 10 pM fura-2 acetoxymethyl in N-2-hydroxyethylpiperazine-W-2-ethanesulfonic acid buffer at 37'C for 5 min. This suspension was then diluted 10-fold in buffer, incubated for 20 min, and resuspended in fresh buffer. This loading protocol optimizes fura-2 acetoxymethyl uptake and its conversion to the free acid fura-2 resulting in a cell-associated concentration of 0.5 pM fura-2. Immediately before use, cells were microfuged and resuspended at a cell concentration to 2.5 x lo9 cells/L. Fluorescence changes were monitored in a stirred suspension of preloaded cells at dual excitation wavelengths of 340 and 380 nm and an emission wavelength of 5 10 nm. Cytosolic CaZ+ concentrations were calculated by the ratio method of Grynkiewicz et al. (33) . For comparison of patients and controls, Ca2+ mobilization was calculated as the area under the curve. This method takes into account both peak height and the rate of recovery, and thus more faithfully represents the extent and time over which Ca2+ was elevated.
02-generation. The generation of 0 2 -by neutrophils and monocytes was measured as superoxide dismutase-inhibitable cytochrome c reduction by a continuous recording spectrophotometric method (34) . Cells were preincubated for 5 min at 37°C before addition of stimulus. 01-generation was monitored for 1 min before addition of ligand to obtain baseline rate. After addition of either f-Met-Leu-Phe or PMA, Oz-generation was monitored for 4 min. The results are expressed as average rate or average amount of 02-production in units of nmol 02-/min/ lo6 cells or nmol 02-/lo6 cells, respectively.
Analysis of C D l l b receptor regulation. Immunofluorescence detection of the CDl lb expression was assessed by using the MAb OKM 1 (anti-CD11 b/CR3; Ortho Diagnostic Systems, Inc., Westwood, MA). Whole blood, collected in EDTA-treated monovette syringes, was placed on ice. After addition of f-Met-LeuPhe M), whole blood was immediately transferred to a 37'C shaking water bath. Aliquots were removed at various timed intervals, the reaction was stopped through dilution with PBS + 0.0 1 % NaN3 + 0.1 % BSA at 4'C, and the aliquots were washed one time. The sampled blood was incubated with positive and irrelevant isotype control MAb (1:s dilution) for 30 min at 4'C, washed twice with PBS + 0.01% NaN3 + 0.1% BSA, and incubated with FITC-conjugated goat F(ab')2 anti-mouse immunoglobulin (1530 dilution; Tago, Burlingame, CA) for 30 min. After lysis of red blood cells, cell preparations were analyzed by flow cytometry (Epics C, Coulter Electronics, Inc., Hialeah, FL) as previously described (3 1). Individual cells from monocyte and neutrophil populations were selectively gated based on forward and right-angle light scatter.
Neutrophil chemotaxis assay. Neutrophil chemotaxis was determined by the agarose method (35) . Chemotaxis plates were prepared with 1.2% agarose containing 10% pooled human serum in modified Eagle's medium. Cells were placed in a central well and 10 pL of attractant were added to an adjoining well. Plates were incubated 2 h at 37°C in 5% C02, then fixed with methanol and formalin. Agarose was removed, and the plates were stained with Wright's stain. Chemotaxis was determined by measuring the distance from the leading front to the central well and subtracting the distance that the cells moved in the opposite direction. Measurements were obtained using an overhead projection microscope with 4 0~ magnification.
Materials. rhG-CSF (sp act = 1 x 10' U/mg of protein) was obtained from Amgen and rhGM-CSF (sp act = 1 x 10' U/mg) was obtained from Genzyme (Cambridge, MA). PMA and fMet-Leu-Phe were purchased from Sigma Cemical Co. (St. Louis, MO). PMA was stored as a concentrated stock solution in DMSO and f-Met-Leu-Phe in ethanol. Both PMA and f-Met-Leu-Phe were diluted in buffer before use. Figure 1 shows the effect of G-CSF therapy on circulating levels of neutrophils and eosinophils. Before the start of G-CSF therapy, the patient's ANC was 336/mm3. G-CSF treatment resulted in a prompt increase in mature circulating neutrophils to 1333 by d 2 of therapy. The patient's ANC remained within the normal range during 8 mo of treatment with an average ANC of 2842 with cell counts fluctuating between 736 and 11 790/mm3. The G-CSF therapy selectively increased only the levels of peripheral blood neutrophils. The number of circulating eosinophils during G-CSF therapy was not significantly different from pre-G-CSF therapy levels (Fig. 1 ).
RESULTS

Eflect of G-CSF administration on peripheral blood counts.
An unexpected side effect of G-CSF therapy is depicted in Figure 2 , which shows the patient's platelet count both before and after G-CSF therapy. Before G-CSF therapy, the patient had an elevated platelet count. This is a common observation in patients with GSD lb, and the reason for this elevation is not known (12) . Interestingly, G-CSF therapy resulted in a reduction of the patient's platelet count to values that stabilized within the normal range.
In vitro and in vivo effects of G-CSF on 0 2 -production and Ca2+ mobilization. G-CSF therapy resulted in significant improvement in the levels of circulating neutrophils, which was coupled with clinical improvement with a decrease in both the rate of infection and the severity of illness. In addition to neutropenia, we previously documented depressed respiratory burst activity in neutrophils and monocytes from GSD lb patients (1 8, 19, 36) . We next determined whether G-CSF also corrected the respiratory burst defect in GSD Ib phagocytic cells.
In vitro cytokine effects on neutrophil 0 2 -generation. To establish whether in vivo use of cytokines would be appropriate for the treatment of the depressed 02-generation in GSD 1 b and to determine whether short-term exposure could alter neutrophil function in GSD 1 b, we first tested these cytokines in vitro. Before G-CSF therapy, the in vitro effects of G-CSF on M f-Met-Leu-Phe-triggered 0 2 -generation were determined in isolated neutrophils from three unrelated GSD lb patients. As shown in Figure 3 , control neutrophils stimulated by f-Met-Leu-Phe produced 02-at a rate of 1.03 k 0.10 nmol/ min/106 cells (mean & SD, n = duplicate determinations of three patients with matched controls). In contrast, neutrophils from GSD Ib patients generated 0 2 -at a rate significantly less than controls (0.36 k 0.04 nmol/min/106 cells, p < 0.01). When control neutrophils were incubated with G-CSF (5 x lo' U/L) 15 min before the addition of f-Met-Leu-Phe, the rate of 02-generation was significantly increased to 2. (Fig. 3A) . However, the rate was still significantly below control values obtained with or without G-CSF pretreatment ( p < 0.01). The effect of GM-CSF on 02-production in neutrophils from controls and GSD 1 b patients was also compared. As shown in Figure 3B , addition of GM-CSF (1.25 U x 105/L) 15 min before stimulation with f-Met-Leu-Phe significantly increased 0 2 -production in control neutrophils to 3.36 & 0.62 nmol/min/106 cells ( p < 0.01). In contrast, the addition of GM-CSF to GSD l b neutrophils before stimulation with f-Met-Leu-Phe did not produce an enhanced respiratory burst (Fig. 3B) .
In vitro cytokine effects on neutrophil Ca2+ mobilization. We have shown previously that the depressed rate of f-Met-Leu-Phetriggered 0 2 -production by GSD I b neutrophils was associated with decreased Ca2+ mobilization (18, 19) . We determined the effects of G-CSF and GM-CSF pretreatment on Ca2+ mobilization in neutrophils from control donors and GSD 1 b patients. As previously reported (25), G-CSF (5 x lo5 U/L) itself did not trigger calcium mobilization in control neutrophils. Moreover, preincubation of control neutrophils with G-CSF for 15 min did not enhance f-Met-Leu-Phe M)-triggered Ca2+ mobilization (Fig. 4A ). In agreement with our previous studies (18, 19) , Ca2+ mobilization was reduced in GSD Ib neutrophils in response to M f-Met-Leu-Phe compared with controls (Fig.  4) . Preincubation with G-CSF (Fig. 48) did not correct the reduced calcium mobilization to f-Met-Leu-Phe stimulation in GSD Ib neutrophils. Pretreatment of neutrophils with GM-CSF (1.25 x 10' U/L) did not trigger Ca2+ mobilization nor did it enhance f-Met-Leu-Phe-stimulated Ca2+ mobilization (data not shown).
Effect of in vivo G-CSF administration on neutrophil 02-generation and Ca2+ mobilization. The effects of G-CSF on neutrophil functions in vivo were determined by obtaining blood samples at various time intervals during therapy and then measuring the rate of 0 2 -generation and Ca2+ mobilization in re-GSD IB NEUTROPHIL FUNCTIONS AND G-CSF 8 7 *. 1000-defective respiratory burst activity (14, 18 1.68 nm0l 02-/lo6 control cells, n = 2). ward f-Met-Leu-Phe was examined. Table 2 the constitutive expression of CD 1 l b on GSD lb neutrophils was similar to that of controls (Fig. 5) . F-Met-Leu-Phe stimula- control neutrophils (Fig. 5 ). There was, however, a difference in
Effect of in vivo G-CSF administration on neutrophil chemotaxis. Defective chemotaxis was previously documented in neu-
Effect of in vivo G-CSF administratiolPon neutrophil CD I I b
the rate of upmodulation of CD 1 lb expression in GSD lb and the rate of receptor up-regulation in response to f-Met-LeuPhe were not significantly different from controls (data not sponse to f-Met-Leu-Phe. Before G-CSF therapy, the patient's shown). neutrophil02-production in response to f-Met-Leu-Phe was 19 f 13% of controls (mean & SD, n = 3 separate neutrophil Table 2 Table 1 , after 2 mo of G-CSF therapy, chemotaxis to JMet-Leu-Phe* f-Met-Leu-Phe-triggered 0 2 -production had improved to a p matic improvement in both 0 2 -production and Ca2+ mobilization to values similar to controls (Table 1) .
. Effect of in vivo G-CSF therapy on GSD Ib neutrophil preparations). As shown in
x M f-Met-Leu-Phe
We previously reported that 02-generation in response to phils (18, 19) . However, after 4 mo of G-CSF therapy, 02- 
DISCUSSION
Patients with GSD lb are distinguished from patients with other forms of GSD by neutropenia, phagocytic celldysfunction, and recurrent bacterial infections. The neutro~enia in GSD lb patients is variable, but ANC are usually le& than 500/mm3. The underlying cause of neutropenia is not known but is thought to be either impaired maturation or ineffective mobilization of the cells into the circulation ( 1 1, 12) . Before G-CSF therapy, the myeloid cells in our patient were increased in the bone marrow and were morphologically normal, with an increase in band forms (data not shown). In agreement with previous studies (4 1-43), the neutropenia associated with GSD Ib was corrected rapidly with administration of G-CSF. The quick response (within 2-3 d) to this therapy suggests that G-CSF triggers demargination of neutrophils into the circulation rather than stimulation of early myeloid precursors, which would require a longer response time such as in the treatment of severe congenital neutropenia (28, 29, 44, 45) .
In contrast to the other studies on GSD lb patients, fluctuations in the neutrophil levels were observed in this patient over the course of G-CSF treatment (41) (42) (43) . The reason for these fluctuations is not clear, and before G-CSF therapy the patient did not demonstrate cyclic neutropenia. This type of fluctuation has been observed in some but not all patients with severe congenital neutropenia receiving G-CSF therapy (44, 45) ; however, the basis for the oscillations in this patient population is not known.
G-CSF therapy also reduced the elevated platelet counts observed in this patient to levels within the normal range. This effect of G-CSF therapy on platelets has been observed in patients with congenital agranulocytosis who have elevated platelet counts in the absence of documented infection (44) . It is not clear whether the drop in platelet counts is due to a decrease in infections or a direct effect of G-CSF resulting in either an inhibition of platelet synthesis or an increase in platelet consumption.
In addition to neutropenia, defective respiratory burst activity and chemotaxis have been reported in both circulating phagocytes and adherent macrophages from GSD lb patients (9, 10, 13-15, 18, 19, 36) . We demonstrated previously that the respiratory burst abnormality was associated with impaired Ca2+ mobilization and decreased Ca2+ stores (18, 19) . The alteration in Ca2+ mobilization is an indication of an impairment in signaling in phagocytic cells from GSD 1 b patients; however, the specific defect has not been identified.
Both G-CSF and GM-CSF are capable of enhancing the responsiveness of mature cells of the immune system (20, 2 1, 46) . Therefore, we determined whether either of these growth factors could correct the respiratory burst defect in GSD 1 b phagocytes. In vitro, neutrophils from GSD lb patients respond with increased 0 2 -generation after short-term preincubation with G-CSF but not with GM-CSF. In vivo, G-CSF therapy resulted in normalized neutrophil02-production to ligand (i.e. f-Met-LeuPhe) and PMA simulation. This finding is in agreement with the studies of Schroten et al. (41) . In addition, the defective Ca2+ mobilization increased concomitantly with the respiratory burst activity, suggesting that these two defects are directly related.
Distinct from previous studies on the effects of G-CSF therapy on GSD lb neutrophil function (41), we have detected a difference between the time courses necessary for correction of the neutropenia and for correction of the respiratory burst activity through in vivo G-CSF therapy. Neutropenia was corrected within several days, but G-CSF therapy resulted in only a gradual correction of neutrophil function that took several months to attain control levels. This suggests that G-CSF is acting in multiple ways during hematopoiesis.
In vivo, G-CSF may correct the respiratory burst through a direct action on mature granulocytes, possibly through some type of priming mechanism. The precise mechanism of neutrophi1 priming by G-CSF has not been elucidated. G-CSF does not appear to act directly on the f-Met-Leu-Phe receptor, rather it works through activation of a signal transduction pathway that is distinct from those that increase cytosolic Ca2+ and activate protein kinase C (24, 25, 27) . Sullivan et al. (25) proposed that enhanced respiratory burst activity in response to pretreatment with G-CSF may be a result of increased arachidonate metabolism and the accumulation of its metabolites. It should be noted, however, that although in vitro G-CSF pretreatment significantly increased the rate of 02-production in GSD 1 b neutrophils, the rate was still significantly less than that in controls. Moreover, we demonstrated that there was a parallel improvement in respiratory burst activity and Ca2+ mobilization during G-CSF therapy, although we could not increase Ca2+ mobilization in vitro with G-CSF. Furthermore, priming does not explain why it takes several months for the correction of the respiratory burst and the need for several generations of neutrophils to be exposed in vivo to G-CSF.
Alternatively, the depressed respiratory burst associated with impaired Ca2+ mobilization could be due to a subpopulation of cells with functional defects accompanied by a subset of neutrophils with functionally normal neutrophils. There is evidence that the defective Ca2+ mobilization we previously documented is the result of defective subpopulations of neutrophils (18, 19, 47) . Accordingly, raising the in vivo levels of G-CSF through therapy may select for differential proliferation of a lineage of cells with normal respiratory burst activity. Nevertheless, the therapeutic effects appear to act at the level of the progenitor cells and not directly on mature neutrophils.
Although G-CSF therapy corrected the neutropenia, as well as the defective respiratory burst activity and associated blunted Ca2+ mobilization, it did not correct the defect in chemotaxis. Thus, the depressed chemotaxis in GSD l b phagocytes appears to be distinct from the defect in respiratory burst activity and Ca2+ mobilization. Indeed, recent studies have suggested that chemotaxis will occur independently of a rise in intracellular Ca2+ (48) . Decreased random and directed migration does not appear to be a result of altered expression of C3bi receptors, inasmuch as there are no significant differences compared with controls in either constitutive expression or f-Met-Leu-Phestimulated receptor expression during G-CSF therapy. G-CSF therapy did, however, alter the rate of upmodulation of C3bi receptor expression in response to f-Met-Leu-Phe. Previous studies on patients with congenital neutropenia and patients undergoing chemotherapy have demonstrated increased expression of neutrophil CD 1 lb antigen with G-CSF therapy (22, 45) . The increased rate of C3bi receptor expression may result in hyperadhesiveness and consequently reduce the chemotactic response (24) . Thus, any correction of the intrinsic chemotactic defect in GSD 1 b neutrophils may have been counteracted due to G-CSFmediated alterations in adherence.
In summary, multiple sites of dysfunction have been identified in phagocytic cells in GSD 1 b including chemotaxis, resuiratory burst activity, and CaZ+ mobilization. ~i present, it is not known whether these phagocytic cell anomalies are a direct result of a primary translocase defect or a secondary effect due to either metabolic consequences or a more fundamental membrane defect. The results of this study demonstrate that cytokine therapy can correct both the neutropenia and the respiratory burst defect in GSD 1 b. G-CSF increased the patient's circulating levels of neutrophils within a few days of therapy. G-CSF therapy also resulted in a gradual correction of the respiratory burst defect with parallel increased Ca2+ mobilization. Therefore, long-term exposure in vivo to G-CSF may be required for correction of both the neutropenia and impaired 02-production in GSD lb patients. Finally, G-CSF therapy significantly reduced the incidence of bacterial infection in this patient, and she has not been hospitalized for the treatment of bacterial infections for more than 1 y since starting G-CSF therapy.
